Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.15 SGD
Change Today 0.00 / 0.00%
Volume 5.4M
QTVC On Other Exchanges
As of 12:59 AM 10/14/15 All times are local (Market data is delayed by at least 15 minutes).

qt vascular ltd (QTVC) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/8/15 - $0.37
52 Week Low
08/21/15 - $0.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QT VASCULAR LTD (QTVC)

Related News

No related news articles were found.

qt vascular ltd (QTVC) Related Businessweek News

No Related Businessweek News Found

qt vascular ltd (QTVC) Details

QT Vascular Ltd. designs, assembles, and distributes therapeutic solutions for the minimally invasive treatment of complex vascular diseases primarily in the United States, Europe, Asia, and internationally. The company offers Chocolate percutaneous transluminal angioplasty (PTA) balloon catheter for the treatment of blocked arteries; GliderXtreme PTA balloon catheter that targets complex lesions in the distal peripheral vasculature; and GliderfleX PTA balloon catheter for use in treating distal peripheral vessels. It also provides Glider percutaneous transluminal coronary angioplasty (PTCA) balloon catheter for the treatment of a range of complex lesions; Chocolate PTCA Balloon Catheter used in dilation of the coronary vascular system; Chocolate Touch, a drug coated balloon; and silk balloon catheter. The company was incorporated in 2013 and is based in Singapore.

Founded in 2013

qt vascular ltd (QTVC) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

qt vascular ltd (QTVC) Key Developments

QT Vascular Ltd. Announces Interim Clinical Trial Results of Chocolate Touch

QT Vascular Ltd. announced the release of the interim results from ENDURE, the first study of its unique peripheral drug-coated balloon, Chocolate Touch. ENDURE is a prospective, core lab adjudicated study of the Chocolate Touch Paclitaxel drug- coated PTA balloon conducted at multiple sites in Germany and New Zealand. The study enrolled 67 patients with above-the-knee disease and assessed outcomes at 30 days and 6 months. There will also be a clinical and duplex ultrasound assessment of patients at 12 months. Unlike most other studies of drug-coated balloons, pre-dilatation was not required for Chocolate Touch and was left to the operator's discretion. Angiographic results were adjudicated by the core lab at Yale University. Duplex ultrasound results were assessed by VASCORE. Drug-coated balloons represent a new category of device that combines the mechanical dilatation of a balloon catheter with the biological effect of a drug to treat occluded arteries. These devices have been available for several years in Europe and were recently approved in the United States. Since their approval in the United States., adoption has been increasing and CMS (Centers for Medicare and Medicaid Services) has granted additional reimbursement for these devices. According to some analysts' estimates, revenues for drug-coated balloons are expected to reach $1 billion by 2020.

Jury in Federal Court in California Finds Against AngioScore's Patent Infringement Claims

The Spectranetics Corporation announced that a jury in the U.S. District Court for the Northern District of California has found against its wholly-owned subsidiary, AngioScore Inc., the plaintiff in a lawsuit seeking damages and other relief for patent infringement against defendants Eitan Konstantino, TriReme Medical, LLC, Quattro Vascular Pte Ltd. and QT Vascular Ltd. related to defendants' Chocolate PTA balloon catheter. The jury also found that certain claims of the asserted patent are invalid. The patent verdict has no impact on the Court's findings or award of damages in connection with the breach of fiduciary duty claims or the ability to recover advanced fees and costs. The patent infringement claims are part of the lawsuit in which the Court previously found that Konstantino, a former board member of AngioScore and founder of TriReme Medical, LLC, and other defendants, breached his fiduciary duties to AngioScore, that TriReme and Quattro aided and abetted that breach, and that QT Vascular is liable for the acts of TriReme and Quattro. In that portion of the case, the Court awarded AngioScore $20.034 million against all defendants plus disgorgement from Konstantino of all benefits he accrued from his breach of fiduciary duties, including amounts he received for assigning his intellectual property rights to the Chocolate balloon, a royalty on past and future sales of the Chocolate balloon, and all of his shares and options in QT Vascular.

QT Vascular Ltd. Appoints Sho Kian Hin as Independent Director

QT Vascular Ltd. announced the appointment of Sho Kian Hin as independent director of the company with effect from September 25, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QTVC:SP $0.15 SGD 0.00

QTVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QTVC.
View Industry Companies

Industry Analysis


Industry Average

Valuation QTVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.1x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QT VASCULAR LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at